CIIHY yields 2.85% · PFE yields 6.20%● Live data
📍 PFE pulled ahead of the other in Year 8
Combined, CIIHY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CIIHY + PFE for your $10,000?
CITIC Securities Company Limited provides various financial products and services in Mainland China and internationally. It operates through Investment Banking, Brokerage, Trading, Asset Management, and Others segments. The company offers investment banking services, including equity and debt financing, as well as fundraising and financial advisory services to a range of enterprises and other institutional clients. It is also involved in the broking of securities and futures; distribution of financial products; and trading and market-making of equity products, fixed income products and derivatives, foreign exchange, margin financing and securities lending, alternative investment, and commodities business. In addition, the company offers asset management services, such as collective asset management, specialized asset management, separately managed account, fund management, and other investment accounts management; private equity investment and other services; and custody and research services. Further, it provides institutional brokerage, investment advisory and management, investment consultancy, fiduciary management, fund, real estate, business training, and financial products and securities investment services. Additionally, the company offers finance outsourcing, bond issuance, offshore portfolio hedge and investment fund, fund distribution, leveraged foreign exchange and other transactions, investment with self-owned capital, cash transactions, property management and leasing, and other services. It also engages in information technology development, technical consulting, research and development of financial products, portfolio design, and consulting activities. CITIC Securities Company Limited was incorporated in 1995 and is based in Beijing, the People's Republic of China.
Full CIIHY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.